Physician profile
Paul J Lama
NPI 1033130315
$72,188.29
in general payments reported to CMS, 2019-2025
17 companies · $6,795 in 2025
The $6,795 reported for 2025 was more than what 90% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $14K · 2021: $9,799 · 2022: $13K · 2023: $3,222 · 2024: $13K · 2025: $6,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $3,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,467.50 |
| Food and Beverage | $3,097.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $31,859.60 | 2019-2025 | Idose, Istent Trabecular Micro-Bypass Stent System, Idosetr |
| Aerie Pharmaceuticals, INC. | $29,425.93 | 2019-2021 | |
| Alcon Vision LLC | $7,720.03 | 2022-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Allergan, INC. | $1,218.59 | 2019-2022 | |
| Abbvie INC. | $589.05 | 2022-2025 | |
| New World Medical,INC. | $496.49 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $378.83 | 2022-2025 | Envista Mx60 Iol, Vyzulta |
| Oyster Point Pharma, INC. | $133.54 | 2022-2024 | Tyrvaya |
| Thea Pharma INC. | $124.16 | 2022-2025 | Iyuzeh |
| Sight Sciences, INC. | $59.52 | 2019-2025 | Sion Surgical Instrument, Omni Surgical System |
| Amgen INC. | $49.88 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $39.66 | 2019 | |
| Sun Pharmaceutical Industries INC. | $32.92 | 2019-2024 | |
| Eyevance Pharmaceuticals LLC | $17.59 | 2023 | Flarex |
| Biotissue Holdings INC. | $14.46 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.40 | 2021 | |
| Kala Pharmaceuticals, INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.